Primary biliary cirrhosis.

Primary biliary cirrhosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Primary biliary cirrhosis. Abstract Text:

Teru Kumagi,E Jenny Heathcote,

Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology characterized by injury of the intrahepatic bile ducts that may eventually lead to liver failure. Affected individuals are usually in their fifth to seventh decades of life at time of diagnosis, and 90% are women. Annual incidence is estimated between 0.7 and 49 cases per million-population and prevalence between 6.7 and 940 cases per million-population (depending on age and sex). The majority of patients are asymptomatic at diagnosis, however, some patients present with symptoms of fatigue and/or pruritus. Patients may even present with ascites, hepatic encephalopathy and/or esophageal variceal hemorrhage. PBC is associated with other autoimmune diseases such as Sjogren's syndrome, scleroderma, Raynaud's phenomenon and CREST syndrome and is regarded as an organ specific autoimmune disease. Genetic susceptibility as a predisposing factor for PBC has been suggested. Environmental factors may have potential causative role (infection, chemicals, smoking). Diagnosis is based on a combination of clinical features, abnormal liver biochemical pattern in a cholestatic picture persisting for more than six months and presence of detectable antimitochondrial antibodies (AMA) in serum. All AMA negative patients with cholestatic liver disease should be carefully evaluated with cholangiography and liver biopsy. Ursodeoxycholic acid (UDCA) is the only currently known medication that can slow the disease progression. Patients, particularly those who start UDCA treatment at early-stage disease and who respond in terms of improvement of the liver biochemistry, have a good prognosis. Liver transplantation is usually an option for patients with liver failure and the outcome is 70% survival at 7 years. Recently, animal models have been discovered that may provide a new insight into the pathogenesis of this disease and facilitate appreciation for novel treatment in PBC.

Primary biliary cirrhosis. Publishing Authors By Initials

T Kumagi,EJ Heathcote,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Primary biliary cirrhosis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Orphanet journal of rare diseases

VOLUME: 3

Page Numbers: 1

Journal Abbreviation:

ISSN: 1750-1172

DAY: 23

MONTH: 01

YEAR: 2008

Primary biliary cirrhosis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101266602

Primary biliary cirrhosis. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Primary biliary cirrhosis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Primary biliary cirrhosis.

AFFILIATION: Department of Medicine, Toronto Western Hospital (University Health Network/University of Toronto), Toronto, Ontario, Canada. masato_teru@yahoo.co.jp

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Orphanet J Rare Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Primary biliary cirrhosis Related Publications

• An integrated model of choices and response times in absolute identification.
• Antimitochondrial antibody-negative primary biliary cirrhosis.
• Antiviral therapy: chronic hepatitis C.
• Compelling EPR evidence that the alternative oxidase is a diiron carboxylate protein.
• Diagnosis and management of cholestatic liver disease.
• Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.
• Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis.
• Flavianates of lysine.
• Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B.
• Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
• Internet access overseas.
• Minimization of the impact of a broad bandwidth high-gain nonlinear preamplifier to the amplified spontaneous emission pedestal of the Vulcan petawatt laser facility.
• Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): A cross-sectional study.
• Ocular involvement in acute febrile neutrophilic dermatosis (sweet syndrome): new cases and review of the literature.
• Oral treatment of pernicious anaemia with low doses of H.P.P./1.
• Oral treatment of pernicious anaemia: first fifty cases.
• Postgraduate medical training: getting patients on board.
• Preface.
• Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: Evaluating the role of routine magnetic resonance imaging.
• Primary biliary cirrhosis.
• Primary biliary cirrhosis: the future.
• Recruiting patients for postgraduate medical training in a community family planning clinic: how do patients want to be asked?
• Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.
• Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: Case reports.
• T regulatory cells and autoimmune liver disease.
• The toxicity of small concentrations of cystine to acid-producing bacteria.
• Three atypical cases of Wilson disease: assessment of the Leipzig scoring system in making a diagnosis.
• Toxic effect of the crystals from agenized zein on certain acid-producing bacteria.
• Treatment of hepatitis B: the next five years.
• What motivates patients to become involved in postgraduate medical training in a family planning clinic?